Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer.

Literature DB >> 12743164

Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer.

Angelo Di Leo, Harry Bleiberg, Marc Buyse.

Abstract

Entities: Disease

Mesh：

Year: 2003 PMID： 12743164 DOI： 10.1200/JCO.2003.99.089

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

25 in total

Review 1. Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer.

Authors: Marc Buyse
Journal: Int J Clin Oncol Date: 2009-04-24 Impact factor: 3.402

Review 2. Bevacizumab in the treatment of metastatic breast cancer: friend or foe?

Authors: Alberto J Montero; Mauricio Escobar; Gilberto Lopes; Stefan Glück; Charles Vogel
Journal: Curr Oncol Rep Date: 2012-02 Impact factor: 5.075

Review 3. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

Authors: Edward L Korn; Boris Freidlin; Jeffrey S Abrams
Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544

4. Trends in endpoint selection in clinical trials of advanced breast cancer.

Authors: Seung Yeon Song; Heenam Seo; Gyungjin Kim; Ah Rong Kim; Eun Young Kim
Journal: J Cancer Res Clin Oncol Date: 2016-09-01 Impact factor: 4.553

5. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.

Authors: Fabrice Andre; Kristine Broglio; Lajos Pusztai; Narjiss Berrada; John R Mackey; Jean Marc Nabholtz; Stephen Chan; Gabriel N Hortobagyi
Journal: Oncologist Date: 2010-04-26

Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer.

Review 1. Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer.

Review 2. Bevacizumab in the treatment of metastatic breast cancer: friend or foe?

Review 3. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

4. Trends in endpoint selection in clinical trials of advanced breast cancer.

5. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.

6. Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.

Review 7. Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint.

8. Progression-free survival as a surrogate endpoint in advanced breast cancer.

9. Time-dependent endpoints as predictors of overall survival in multiple myeloma.

10. Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer.